SCHEMBL7205506

SCHEMBL7205506

COc1ccc(-c2cc3cc(OC)cc(C)c3c3ccc(C(=O)C(C)C)cc23)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.57
ESR2 Q92731 4/20 0.44
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GRM2 Q14416 1/20 0.39
KDM4E B2RXH2 2/20 0.38
RECQL P46063 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.38
POLB P06746 2/20 0.37
GAA P10253 2/20 0.37
GRK6 P43250 1/20 0.37
BLM P54132 1/20 0.37
GFER P55789 1/20 0.37
PLAU P00749 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
DBH P09172 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
GPR84 Q9NQS5 1/20 0.35
BACE1 P56817 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7205812 0.87 ESR2 (0.55) ESR1ESR2MEN1KMT2AGRM2
SCHEMBL7203855 0.81 ESR1 (0.65) ESR1ESR2KDM4ERECQLGAA
SCHEMBL7204491 0.71 MEN1 (0.50) ESR2MEN1KMT2AGRM2KDM4E
SCHEMBL16346363 0.70 KDM4E (0.66) MEN1KMT2AKDM4ERECQLALDH1A1
SCHEMBL678080 0.70 CES2 (0.55) ESR2ALDH1A1CYP1A2
SCHEMBL12453 0.68 CES2 (0.61) MEN1KMT2AALDH1A1HPGDRXFP1
SCHEMBL7205374 0.67 ESR2 (0.63) ESR1ESR2KDM4EALDH1A1HPGD
SCHEMBL13408700 0.66 ACACA (0.59) KDM4EALDH1A1HPGDGPR84BACE1
SCHEMBL13601948 0.66 MAPT (0.43) ESR2MEN1KMT2AKDM4EALDH1A1
SCHEMBL757099 0.65 HTT (0.55) MEN1KMT2AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599921-B2 Antiproliferative agents against estrogen-dependent cancer cells dibenzothiopyran, dibenzopyran and phenanthrene derivatives NANODESIGN, INC. (CA) 2003-07-29 US disclosed
US-20020156077-A1 Non-steroidal estrogen receptor ligands PALOMA PHARMACEUTICALS, INC. 2002-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156077-A1 Non-steroidal estrogen receptor ligands ESRRA, ESRRB, ESRRG ESR1 6/4885ESR2 4/4885MEN1 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.